Claims for Patent: 4,737,462

Summary for Patent: 4,737,462

Title:	Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-.beta.
Abstract:	A modified IFN-.beta. is provided wherein the cysteine residue at position 17 is deleted and serine is substituted therefor. DNA sequences coding for the modified protein, nucleotide primers used for the mutagenesis, appropriate cloning vectors, host organisms transformed with the vectors, methods for the production and use of the modified IFN-.beta. (IFN-.beta..sub.ser17) are also provided. The specific activity of IFN-.beta..sub.ser17 is found to be substantially the same as that of native IFN-.beta..
Inventor(s):	Mark; David F. (Hercules, CA), Lin; Leo S. (Fremont, CA), Yu Lu; Shi-Da (Oakland, CA)
Assignee:	Cetus Corporation (Emeryville, CA)
Application Number:	06/753,717
Patent Claims:	1. A structural gene having a DNA sequence that encodes a synthetic IFN-.beta. wherein the cysteine residue at position 17, numbered in accordance with native human IFN-.beta., is replaced by a neutral amino acid. 2. The structural gene of claim 1 wherein the neutral amino acid is selected from the group consisting of serine, threonine, glycine, alanine, valine, leucine, isoleucine, histidine, tyrosine, phenylalanine, tryptophan, and methionine. 3. The structural gene of claim 1, wherein the neutral amino acid is serine or threonine. 4. The structural gene of claim 1, wherein the neutral amino acid is serine. 5. The structural gene of claims 1, 2, 3, or 4 with or without an initial ATG codon. 6. The structural gene as represented in FIG. 10, with or without the initial ATG codon. 7. An expression vector that includes that structural gene of claims 1, 2, 3 or 4. 8. The plasmid having an NRRL accession number B-15356. 9. A host cell transformed with an expression vector that includes a structural gene having a DNA sequence that encodes a synthetic IFN-.beta. wherein the cysteine residue at position 17, numbered in accordance with native human IFN-.beta., is replaced by a neutral amino acid and said mutein exhibits the biological activity of native human IFN-.beta., wherein the host cell is selected from the group consisting of bacteria, yeast, animal, and plant. 10. The host cell of claim 9, wherein the host cell is bacteria. 11. The host cell of claim 10, wherein the bacteria is E. coli. 12. The host cell of claims 9, 10 or 11, wherein the neutral amino acid is selected from the group consisting of serine, threonine, glycine, alanine, valine, leucine, isoleucine, histidine, tyrosine, phenylalanine, tryptrophan, and methionine. 13. The host cell of claims 9, 10 or 11, wherein the neutral amino acid is serine. 14. E. coli transformed by an expression vector which includes the structural gene represented by FIG. 10, with or without the initial ATG codon. 15. E. coli transformed with the plasmid pSY2501 and progeny thereof.

Details for Patent 4,737,462

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bayer Healthcare Pharmaceuticals Inc.	BETASERON	interferon beta-1b	For Injection	103471	07/23/1993		2005-04-12

International Patent Family for US Patent 4,737,462

Country	Patent Number	Estimated Expiration
South Africa	837789
United States of America	RE33653
United States of America	4853332